Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of HLC-001 in steroid refractory idiopathic pneumonia syndrome after HSCT
jRCT2033250788Phase 3Recruiting
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Apr 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial in Idiopathic Pneumonia Syndrome (IPS) comparing HLC-001 with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
HLC-001
03
Conditions
Idiopathic Pneumonia Syndrome (IPS)
Beyond the preview
Go deeper on jRCT2033250788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250788.